Uncategorized
ForeseeHome AMD monitoring program available for Medicare patients in US
The ForeseeHome AMD monitoring program is available by prescription for eligible Medicare patients in the U.S. who have dry age-related macular degeneration and are at risk for developing wet AMD, Notal Vision announced in a press release. “Notal Vision is extremely pleased to achieve this significant milestone with the ForeseeHome AMD monitoring system. We have worked diligently for almost 2 years with the goal of ensuring this device is available to eligible patients enrolled in Medicare,” Barak Azmon, MD, CEO of Notal Vision, said in the release.